rawfin.tv
Amgen Shares Decline Following Novartis Cardiovascular Drug Trial Failure
MarketsstocksAI Generated

Amgen Shares Decline Following Novartis Cardiovascular Drug Trial Failure

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Amgen's stock fell 10% after Novartis reported a failed clinical trial for a rival cardiovascular drug, impacting investor sentiment for the sector. Other stocks like Intel, Qualcomm, and Rigetti are also under watch for various market factors.

BiotechnologyPharmaceuticalsSemiconductorsClinical Trials

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks